Koers Cytori Therapeutics Inc Nasdaq
Aandelen
US23283K4022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 3,4 mln. 3,16 mln. | Omzet 2025 * | 2,87 mln. 2,66 mln. | Marktkapitalisatie | 9,24 mln. 8,58 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -21 mln. -19,5 mln. | Nettowinst (verlies) 2025 * | -29 mln. -26,93 mln. | EV/omzet 2024 * | 2,72 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,22 x |
K/w-verhouding 2024 * |
-0,9
x | K/w-verhouding 2025 * |
-0,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,77% |
Recentste transcriptie over Cytori Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 06-02-20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 27-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Richard Hawkins
CHM | Chairman | 75 | 01-12-07 |
Robert Lenk
BRD | Director/Board Member | 75 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |